Physician profile
Sol Cowart
NPI 1124760939
$457.18
in general payments reported to CMS, 2019-2025
14 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.94 · 2023: $85.80 · 2024: $122 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $61.56 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $53.05 | 2023-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $50.68 | 2023-2025 | |
| Corcept Therapeutics | $50.56 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $43.64 | 2022-2023 | |
| Eisai INC. | $30.84 | 2025 | |
| Medtronic, INC. | $30.52 | 2025 | Minimed 780g |
| Renalytix Ai, INC. | $22.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.95 | 2024 | Xarelto |
| Amgen INC. | $19.52 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $19.04 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $18.69 | 2024 | Airsupra |
| Astellas Pharma US INC | $18.48 | 2024 | Veozah |
| Shield Therapeutics INC | $14.66 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sol Cowart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.